02/01/12 - Sophia-Antipolis, France

MEDIAN signe un contrat majeur avec Sanofi

MEDIAN Technologies signe un contrat majeur avec le laboratoire SANOFI pour l’interprétation et la gestion des images dans une nouvelle étude de phase II sur le cancer du poumon à petites cellules.

 
More info >  (413.2 Kb, PDF File)

02/01/12 - Sophia-Antipolis, France

MEDIAN has signed a landmark contract with Sanofi

MEDIAN Technologies has signed a landmark contract with the top pharmaceutical company SANOFI for medical image interpretation and management in a new phase II study on small cells lung cancer.

 
More info >  (408.8 Kb, PDF File)
 

Testimonials

< Back to Testimonial List
Dr. Catherine Beigelman
La Pitié-Salpêtrière Hospital - Paris, France
Catherine Beigelman, MD, is specialist in thoracic imaging at La Pitié-Salpêtrière hospital, Paris, France. She reads over 20 thoracic CT scans per day for multiple indications such as detection of broncho-pulmonary cancer, search for lung metastasis or for pulmonary emboli.

“The detection and follow-up of pulmonary lesions is a very long and tedious task”, says Dr. Beigelman. “When doing a temporal comparison, it is necessary to find for each nodule the equivalent anatomical location in the two examinations, taking into account the difference of breath-hold. In addition, it is important to be aware that the sensitivity of a human observer is low, especially for small nodules lower than 4 mm”.

Dr. Beigelman strongly believes in the benefits of CAD. “Considering the large amount of time usually spent to detect nodules, a tool highlighting regions of interest for the physician review is valuable.” MEDIAN LMS-Lung helps her in this way, it highlights regions of interest that she then chooses to validate or not.

According to Dr. Beigelman, the performance of MEDIAN LMS-Lung is very good. “We have evaluated the detection sensitivity with MEDIAN LMS-Lung and it is around 85% for solid nodules, which is very good considering that the sensitivity of a human observer is around 60%. This improves our confidence considerably. In addition, LMS-Lung provides automatic volumetric measurements, which are much more accurate than our manual measurements. This enables us to accurately track the evolution of the disease”.

Dr. Beigelman is also convinced that the use of MEDIAN LMS-Lung represents a considerable gain of time. “A follow-up done without any automatic tool can take up to 20 minutes. With LMS-Lung follow-up application, it takes only a couple of minutes once the nodules are validated. In addition, the report providing detailed information and images about the validated nodules contributes to a better communication with the clinicians, especially with the oncologists.”

A study has been carried out by Dr. Beigelman on a specific type of nodule known as non-solid nodules, which are nodules of lower density than solid nodules. “This type of nodule is very important, because their prevalence of malignancy is ten times higher than the solid nodules. Their frequency is increasing because of the high spatial resolution provided by the latest generation of multi-detector CT”. Dr. Beigelman studied and evaluated 250 lesions of this type and the results were very impressive. “We came to the conclusion that MEDIAN LMS-Lung enables us to detect 68% of that type of lesions which is far superior to what a human observer can detect”.